Stocks
Nymox Pharmaceutical CorporationNYMX
NASDAQHealthcareBiotechnology$0.20-0.05%
Focused on developing treatments for prostate and bladder diseases, this small-cap biopharma has drawn investor attention for its late-stage drug candidate targeting benign prostatic hyperplasia. The company's niche focus and clinical pipeline make it a speculative play in the urology therapeutics space.
Market Cap: $18.2M52W Range: $0.17 – $0.74
Congressional Interest in Nymox Pharmaceutical Corporation (NYMX)
1 member of Congress has disclosed 1 trade in Nymox Pharmaceutical Corporation (NYMX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading NYMX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-22 | Greg Francis Murphy | sell | $50K – $100K |